D R Uges

Author PubWeight™ 54.93‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Clozapine-induced agranulocytosis: a case report. Immunopathophysiological considerations. Neth J Med 1998 1.98
2 Combination therapy with cisplatin: modulation of activity and tumour sensitivity. Clin Oncol (R Coll Radiol) 1992 1.43
3 Pharmacokinetics of piperacillin and tazobactam in critically ill patients with renal failure, treated with continuous veno-venous hemofiltration (CVVH). Intensive Care Med 1997 1.35
4 Characterization of a human small cell lung carcinoma cell line with acquired resistance to cis-diamminedichloroplatinum(II) in vitro. Cancer Res 1988 1.21
5 Surface roughness, porosity and wettability of gentamicin-loaded bone cements and their antibiotic release. Biomaterials 2000 1.20
6 Influence of docosahexaenoic acid on cisplatin resistance in a human small cell lung carcinoma cell line. J Natl Cancer Inst 1989 1.16
7 Vincristine pharmacokinetics after repetitive dosing in children. Cancer Chemother Pharmacol 1999 1.14
8 Differential expression of DNA topoisomerase II alpha and -beta in P-gp and MRP-negative VM26, mAMSA and mitoxantrone-resistant sublines of the human SCLC cell line GLC4. Br J Cancer 1996 1.12
9 Validity and reliability of self-reported exposure to environmental tobacco smoke in work offices. J Occup Environ Med 1997 1.08
10 Pharmacokinetics of vincristine in children and adolescents with acute lymphocytic leukemia. J Pediatr 1994 1.07
11 Electrochemical and surface characterization of a nickel-titanium alloy. Biomaterials 1998 1.05
12 Phase II study of oral platinum drug JM216 as first-line treatment in patients with small-cell lung cancer. J Clin Oncol 1999 0.97
13 4-Aminopyridine kinetics. Clin Pharmacol Ther 1982 0.97
14 Mechanism of hyperthermic potentiation of cisplatin action in cisplatin-sensitive and -resistant tumour cells. Br J Cancer 1997 0.97
15 Continuous infusion of ceftazidime in febrile neutropenic patients with acute myeloid leukemia. Eur J Clin Microbiol Infect Dis 1995 0.96
16 [A patient with acute tubular necrosis as a consequence of drinking diethylene glycol-treated wine]. Ned Tijdschr Geneeskd 1987 0.96
17 The role of glutathione in resistance to cisplatin in a human small cell lung cancer cell line. Br J Cancer 1990 0.94
18 Circulating plasma platinum more than 10 years after cisplatin treatment for testicular cancer. Lancet 2000 0.92
19 Impairment of organ function after oral ingestion of refined petrol. Intensive Care Med 1988 0.92
20 Effective treatment of verapamil intoxication with 4-aminopyridine in the cat. J Clin Invest 1984 0.89
21 Cellular basis for differential sensitivity to cisplatin in human germ cell tumour and colon carcinoma cell lines. Br J Cancer 1995 0.88
22 The use of an alum irrigation in the treatment of massive bladder haemorrhage. Pharm Weekbl Sci 1989 0.87
23 A phase I study of 1,2-diamminomethyl-cyclobutane-platinum (II)-lactate (D-19466; lobaplatin) administered daily for 5 days. Br J Cancer 1993 0.87
24 The uncoupling of biliary lipid from bile acid secretion by organic anions in the rat. Gastroenterology 1990 0.87
25 Phase I and pharmacokinetic study of the topoisomerase II catalytic inhibitor fostriecin. Br J Cancer 1999 0.86
26 Pharmacokinetics of high-dose oral and intravenous dexamethasone. Ther Drug Monit 1999 0.86
27 Enhancement of cisplatin and etoposide cytotoxicity after all-trans retinoic-acid-induced cellular differentiation of a murine embryonal carcinoma cell line. Int J Cancer 1993 0.85
28 Vincristine disposition in children with acute lymphoblastic leukemia. Med Pediatr Oncol 1995 0.85
29 Excretion of platinum into breast milk. Lancet 1989 0.84
30 High-dose cyclophosphamide or melphalan with escalating doses of mitoxantrone and autologous bone marrow transplantation for refractory solid tumors. Cancer Res 1989 0.84
31 Valproic acid toxicokinetics: serial hemodialysis and hemoperfusion. Ther Drug Monit 1999 0.83
32 Antidepressants self-poisoning and ICU admissions in a university hospital in The Netherlands. Pharm World Sci 2000 0.83
33 An automated method for the bioanalysis of vincristine suitable for therapeutic drug monitoring and pharmacokinetic studies in young children. Ther Drug Monit 2001 0.83
34 A phase I study of a new polyamine biosynthesis inhibitor, SAM486A, in cancer patients with solid tumours. Br J Cancer 2000 0.82
35 Penetration of isoniazid, rifampicin and pyrazinamide in tuberculous pleural effusion and psoas abscess. Int J Tuberc Lung Dis 2004 0.82
36 Neurotoxicity caused by valacyclovir in a patient on hemodialysis. Ther Drug Monit 1998 0.82
37 Randomized comparison of etoposide pharmacokinetics after oral etoposide phosphate and oral etoposide. Br J Cancer 1997 0.82
38 Effects of c-myc oncogene modulation on drug resistance in human small cell lung carcinoma cell lines. Anticancer Res 1996 0.81
39 A phase I and pharmacokinetic study with 21-day continuous infusion of epirubicin. J Clin Oncol 1987 0.81
40 A study of human small-cell lung carcinoma (hSCLC) cell lines with different sensitivities to detect relevant mechanisms of cisplatin (CDDP) resistance. Int J Cancer 1990 0.80
41 Hyperthermic isolated limb perfusion with cisplatin in four patients with sarcomas of soft tissue and bone. Eur J Surg Oncol 1996 0.80
42 Continuous carboplatin infusion during 6 weeks' radiotherapy in locally inoperable non-small-cell lung cancer: a phase I and pharmacokinetic study. Br J Cancer 1995 0.80
43 Conversion of the prodrug etoposide phosphate to etoposide in gastric juice and bile. Br J Cancer 1997 0.79
44 Continuous infusion carboplatin on a 21-day schedule: a phase I and pharmacokinetic study. J Clin Oncol 1991 0.79
45 Phase II and pharmacokinetic study of lobaplatin in patients with relapsed ovarian cancer. Br J Cancer 1995 0.78
46 Phase I-II study of the addition of alpha-2a interferon to 5-fluorouracil/leucovorin. Pharmacokinetic interaction of alpha-2a interferon and leucovorin. Eur J Cancer 1993 0.78
47 Stability of the new anticancer platinum analogue 1,2-diaminomethyl-cyclobutane-platinum(II)-lactate (lobaplatin; D19466) in intravenous solutions. Pharm Res 1992 0.78
48 Adsorptive voltametry to determine platinum levels in plasma from testicular cancer patients treated with cisplatin. Ther Drug Monit 2001 0.78
49 4-aminopyridine; analysis of the substance and a method for the preparation of a solution for injection in man. Pharm Acta Helv 1981 0.78
50 Hyperthermic isolated regional perfusion with cisplatin in the local treatment of spontaneous canine osteosarcoma: assessment of short-term effects. J Surg Oncol 1995 0.78
51 Renal dysfunction following high-dose carboplatin treatment. J Cancer Res Clin Oncol 1988 0.77
52 A phase I pharmacokinetic study of 21-day continuous infusion mitoxantrone. J Clin Oncol 1989 0.77
53 4-Aminopyridine tablets; a method for the preparation. In-vitro and in-vivo studies. Pharm Acta Helv 1982 0.77
54 Continuous infusion of low-dose doxorubicin, epirubicin and mitoxantrone in cancer chemotherapy: a review. Pharm Weekbl Sci 1988 0.76
55 4-Aminopyridine and haemodialysis in the treatment of verapamil intoxication. Hum Toxicol 1985 0.76
56 In vitro and in vivo modulation of multi-drug resistance with amiodarone. Int J Cancer 1991 0.76
57 Cisplatin and platinum pharmacokinetics during hyperthermic isolated limb perfusion for human tumours of the extremities. Br J Cancer 1992 0.76
58 A prolonged methoxymorpholino doxorubicin (PNU-152243 or MMRDX) infusion schedule in patients with solid tumours: a phase 1 and pharmacokinetic study. Br J Cancer 2000 0.75
59 [A child with puzzling complaints--does he have a disease?]. Ned Tijdschr Geneeskd 1999 0.75
60 Pharmacokinetics of carboplatin at a dose of 750 mg m-2 divided over three consecutive days. Br J Cancer 1990 0.75
61 Magnesium and phosphorus. Lancet 1998 0.75
62 Pharmacokinetics of MEN-10755, a novel anthracycline disaccharide analogue, in two phase I studies in adults with advanced solid tumours. Cancer Chemother Pharmacol 2001 0.75
63 Treatment of 4-aminopyridine-poisoning after oral overdose; a proposal. Pharm Acta Helv 1984 0.75
64 Sensitive method for the determination of vincristine in human serum by high-performance liquid chromatography after on-line column-extraction. J Chromatogr 1991 0.75
65 [Regional isolation perfusion with cisplatinum in dogs with osteosarcoma of an extremity]. Tijdschr Diergeneeskd 1987 0.75
66 Clinical pharmacokinetics of (NPAz2)2NSOAz: 'SOAz'. Cancer Chemother Pharmacol 1983 0.75
67 Influence of oral atropine or hyoscine on the absorption of oral diazepam. Br J Anaesth 1982 0.75
68 Changed pharmacokinetics under the influence of age. Pharm Weekbl Sci 1987 0.75
69 Determination of the antitumor agent SOAz (1,3,3,5,5 pentakis(aziridino)-1 lambda 6,2,4,6,3 lambda 5, 5 lambda 5 thia-triazadiphosphorine-1-oxide) by a gas chromatographic assay suitable for pharmacokinetic studies in man. Cancer Chemother Pharmacol 1983 0.75
70 Effect of ultrafilterable platinum concentration on cisplatin and carboplatin cytotoxicity in human tumor and bone marrow cells in vitro. Pharm Res 1994 0.75
71 Neurophysiological evaluation in children with Friedreich's ataxia. Early Hum Dev 2009 0.75
72 Comparison of the precision of seven analytical methods for the H2O concentration in human serum and urine. Clin Chim Acta 1987 0.75
73 Phase I and pharmacokinetic study of trans-N3P3Az2(NHMe)4. Cancer Treat Rep 1987 0.75
74 Clinical and pharmaceutical aspects in acute poisoning. Pharm Weekbl Sci 1992 0.75
75 Blood concentrations after accidental cyclosporin overdose. Eur J Pediatr 1989 0.75
76 Treatment of severe parathion intoxication. Vet Hum Toxicol 1979 0.75
77 Determination of monoureides in biological fluids by high-pressure-liquid-chromatography. Arch Toxicol 1979 0.75
78 The bone collector: a new device. Arch Otolaryngol 1978 0.75
79 Liquid-chromatographic determination of 4-aminopyridine in serum, saliva, and urine. Clin Chem 1981 0.75
80 Pharmacokinetics of cyclosporine A after intravenous and oral administration in liver transplant patients measured with high-performance liquid chromatography. Ther Drug Monit 1993 0.75